Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Conferences

Conference Coverage

Conference Listing

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on 

Articles

CHOICE2 found intraarterial alteplase after thrombectomy raised the odds of excellent outcomes following large-vessel occlusion ischemic stroke. 

Intraarterial Alteplase After Thrombectomy May Improve Stroke Recovery: CHOICE2

Finance Committee leaders propose expanding Medicare negotiation, curbing middlemen, and reinvesting in biomedical innovation as part of a 2026 health care affordability strategy.

Senate Democrats Outline Drug Pricing Agenda to Cut Patient Costs

Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.

She has a BA in English from Penn State University. You can connect with Maggie on 

Real-world inotuzumab ozogamicin boosts remission in relapsed/refractory B-cell ALL, supports transplant, and flags sinusoidal obstruction syndrome risk.

Inotuzumab Ozogamicin Outcomes in ALL Validated Outside of Clinical Trials

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

More than half of the young patients with myasthenia gravis (MG) responded well to the use of corticosteroids.

Ocular MG an Independent Predictor of MG Responsive to Corticosteroids

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

1.125rem

Partner in Frier Levitt’s Life Sciences Department and heads the firm’s Pharmacy Practice Group.

The Consolidated Appropriations Act of 2026 features new language that could change the way that pharmacy benefit managers (PBMs) operate in the US.

New Regulations on PBMs Become Law: What This Means for Pharmacies Nationwide—A Q&A With Jesse Dresser, Esq